Stockscreener 앱 받기
22.57
2.50%
0.55
시간 외 거래:
22.57
전일 마감가:
$22.02
열려 있는:
$21.85
하루 거래량:
647.58K
Relative Volume:
0.72
시가총액:
$913.86M
수익:
$726.41M
순이익/손실:
$7.03M
주가수익비율:
143.67
EPS:
0.1571
순현금흐름:
$136.66M
1주 성능:
-4.08%
1개월 성능:
-2.63%
6개월 성능:
-15.34%
1년 성능:
-7.04%
1일 변동 폭
$21.85
$22.87
1주일 범위
$21.16
$24.10
52주 변동 폭
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.57 | 891.59M | 726.41M | 7.03M | 136.66M | 0.1571 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-11-17 | 개시 | H.C. Wainwright | Buy |
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - GuruFocus
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 - Investing.com
Pacira BioSciences (PCRX) director receives 6,163 restricted stock units in equity grant - Stock Titan
Pacira BioSciences (NASDAQ: PCRX) CMO sells 3,261 company shares - Stock Titan
Pacira BioSciences (PCRX) director sells 500 common shares in open market - Stock Titan
Pacira faces board fight as activist investor criticizes CEO pay, missed earnings - MSN
Pacira BioSciences unveils support hub for caregivers addressing chronic pain - Traders Union
[144] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Shares Down 4.7%Time to Sell? - MarketBeat
PCRX (NASDAQ: PCRX) insider sale notice lists 3 share lots - Stock Titan
Profit Review: Will Pacira BioSciences Inc benefit from seasonality2026 Big Picture & Weekly High Return Stock Opportunities - baoquankhu1.vn
Radcliffe Capital Management L.P. Takes $1.23 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences advances non opioid pain therapies to transform patient care - Traders Union
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - Sahm
Activist DOMA takes 7.3% Pacira (NASDAQ: PCRX) stake and targets CEO, board - Stock Titan
Pacira BioSciences responds to DOMA director nominations - Investing.com Australia
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - Morningstar
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings - Benzinga
DOMA Perpetual Nominates Three Highly Qualified Candidates for t - GuruFocus
Pacira BioSciences responds to DOMA director nominations By Investing.com - Investing.com UK
DOMA nominates three for Pacira Biosciences (NASDAQ: PCRX), holds 7.1% - Stock Titan
Pacira BioSciences shares rise 2% as activist pushes for CEO removal - Investing.com Canada
Pacira BioSciences (NASDAQ:PCRX) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Liquidity Mapping Around (PCRX) Price Events - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Pacira BioSciences, Inc. $PCRX Shares Purchased by American Century Companies Inc. - MarketBeat
Earnings Beat: Does Pacira BioSciences Inc have consistent dividend growthQuarterly Profit Review & Accurate Entry/Exit Alerts - baoquankhu1.vn
Pacira (PCRX) Grants Inducement Awards to New Employees - GuruFocus
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Presents a Compelling Value Investment Case - ChartMill
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4.6%What's Next? - MarketBeat
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
Pacira BioSciences, Inc. Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - simplywall.st
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Wall Street Zen Downgrades Pacira BioSciences (NASDAQ:PCRX) to Buy - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative - simplywall.st
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):